Ginkgo Bioworks Acquires Proof Diagnostics, Growing Gene Editing Service Offerings for its Customers
Acquiring Company
Ginkgo Bioworks
Acquired Company
Proof Diagnostics
BostonCambridgeOtherManufacturingBiotechnologySustainabilitySoftwareScience And EngineeringBiotechnologyHealth CareDescription
Ginkgo Bioworks has announced the acquisition of Proof Diagnostics, enhancing its gene editing service offerings. Proof Diagnostics, known for developing genome engineering tools and a smart, portable system for disease detection using CRISPR-based and other technologies, will contribute its OMEGA RNA programmable, non-Cas enzymes and associated intellectual property to Ginkgo. The integration of Proof's technologies aims to provide Ginkgo's customers with a new tool to overcome the limitations of current gene editing systems, expanding the company's genetic medicines programs to better serve customers and patients.
Quick answer
Ginkgo Bioworks is acquiring Proof Diagnostics, announced February 28, 2024. Ginkgo Bioworks is based in Boston, Massachusetts, United States.
- How much did Ginkgo Bioworks pay for Proof Diagnostics?
- The deal value was not disclosed.
- What does Ginkgo Bioworks do?
- Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to..
- Where are Ginkgo Bioworks and Proof Diagnostics based?
- Ginkgo Bioworks is based in Boston, Massachusetts, United States. Proof Diagnostics is based in Cambridge, Massachusetts, United States.
- Who are the decision-makers at Ginkgo Bioworks?
- Fundz holds 3 contacts at Ginkgo Bioworks. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Other recent acquisitions in Sustainability and Science And Engineering
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Ginkgo Bioworks completes acquisition of Modulus Therapeutics' Cell Therapy Assets to bolster CAR Designs (April 2, 2024)
- Ginkgo Bioworks completes acquisition of AgBiome's Platform Assets to expand biosecurity and ag biological discovery and development capabilities (April 11, 2024)
- Nuvation Bio Inc. completes acquisition of AnHeart Therapeutics Ltd. to enhance its oncology pipeline (April 10, 2024)
- Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction (March 25, 2024)
- J&J Snack Foods acquires Thinsters® cookie brand from The Hain Celestial Group (April 9, 2024)
- Henry Schein completes acquisition of Majority Interest of TriMed, Inc. to strengthen orthopedic solutions (April 4, 2024)
Who to call at Ginkgo Bioworks, and when
When Ginkgo Bioworks changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Ginkgo Bioworks raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Ginkgo Bioworks, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Ginkgo Bioworks. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Ginkgo Bioworks makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Proof Diagnostics?
Proof Diagnostics was acquired by Ginkgo Bioworks, based in Boston. The deal was reported on February 28, 2024. Ginkgo Bioworks is publicly traded (DNA) and operates in Other.
When did Ginkgo Bioworks acquire Proof Diagnostics?
Ginkgo Bioworks's acquisition of Proof Diagnostics was reported on February 28, 2024. Ginkgo Bioworks has announced the acquisition of Proof Diagnostics, enhancing its gene editing service offerings. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Proof Diagnostics do?
Proof Diagnostics is an innovative life sciences tools, diagnostics, and computational discovery company, founded by gene editing pioneers Dr. Feng Zhang, Drs. Omar Abudayyeh, and Jonathan Gootenberg, and Sid Shenai. It is privately held, operating in Biotechnology, and is based in Cambridge.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.